2026年4月17日，北京大学博雅讲席教授、昌平实验室领衔科学家、生命科学学院邓宏魁课题组在国际学术期刊《细胞》（Cell）上发表了题为“p53 safeguards chemical reprogramming of human somatic cells toward pluripotency”的研究论文。该研究发现，关键肿瘤抑制因子p53在化学重编程中发挥核心保护作用，打破了“p53阻碍细胞 ...

撰文丨王聪编辑丨王多鱼排版丨水成文2006 年，山中伸弥通过病毒载体将 Oct4、Sox2、Klf4和 c-Myc四个转录因子（也称为山中因子）导入成体细胞，将其重编程为诱导多能干细胞（iPS 细胞），他也因这一成就获得了 2012 ...

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...

GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...

In recent years, we have come to appreciate that loss or dysfunction of insulin-producing islet beta cells underlies virtually all major forms of diabetes mellitus. In type 1 diabetes, beta cells ...

An intestinal pathogen reshapes the gut environment to fuel its own colonization and cause diseases, a multi-institutional ...

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American NEW YORK—Despite a cloud of regulatory ...